USA News Group News Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, Aug. 28, 2025 /CNW/ -- Federal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fill the gap, with oncology ventures securing hundreds of millions in funding so far in 2025. The Senate's recent restoration of $15 million for the Pancreatic Cancer Research Program (PCARP) was a win, yet its earlier elimination underscored the fragility of public support. Against this backdrop, investors are zeroing in on companies with standout science, solid pipelines, and clear regulatory strategies, including Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio, Inc. (NASDAQ:IBRX), Agenus Inc. (NASDAQ:AGEN), Sutro Biopharma, Inc. (NASDAQ:STRO), and Castle Biosciences, Inc. (NASDAQ:CSTL).
Read more at newswire.ca